Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received a filing notice from the China Securities Regulatory Commission approving its application for H share full circulation. The approval covers the conversion of a total of 8,214,278 domestic and unlisted foreign shares into H shares, paving the way for greater liquidity and integration of its share classes in Hong Kong.
The company has not yet finalized the detailed implementation plan or the specific arrangements for conversion and listing of these shares. Management said it will issue further announcements as required by Hong Kong listing rules, while cautioning shareholders and potential investors that the process remains subject to additional procedures by the Stock Exchange and other domestic regulators.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$526.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company incorporated in the People’s Republic of China. It focuses on developing and commercializing biotech-driven pharmaceutical products and accesses international capital markets through its H-share listing on the Hong Kong Stock Exchange.
Average Trading Volume: 552,086
Technical Sentiment Signal: Buy
Current Market Cap: HK$99.66B
For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.